Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 26;19(9):2613-2617.
doi: 10.22034/APJCP.2018.19.9.2613.

Survival Analysis of Glioblastoma Multiforme

Supapan Witthayanuwat  1 , Montien Pesee, Chunsri Supaadirek, Narudom Supakalin, Komsan Thamronganantasakul, Srichai Krusun
Affiliations

Survival Analysis of Glioblastoma Multiforme

Supapan Witthayanuwat et al. Asian Pac J Cancer Prev. .

Abstract

Introduction: To evaluate the survival of Glioblastoma Multiforme (GBM). Material and Methods: Patients with a pathological diagnosis of Glioblastoma Multiforme (GBM) between 1 January 1994 and 30 November 2013, were retrospectively reviewed. Inclusion criteria: 1) GBM patients with confirmed pathology, 2) GBM patients were treated by multimodality therapy. Exclusion criteria: 1) GBM patients with unconfirmed pathology, 2) GBM patients with spinal involvement, 3) GBM patients with incomplete data records. Seventy-seven patients were treated by multimodality therapy such as surgery plus post-operative radiotherapy (PORT), post-operative Temozolomide (TMZ) concurrent with radiotherapy (CCRT), post-operative CCRT with adjuvant TMZ. The overall survival was calculated by the Kaplan-Meier method and the log-rank test was used to compare the survival curves. A p-value of ≤ 0.05 was considered to be statistically significant. Results: Seventy-seven patients with a median age of 53 years (range 4-76 years) showed a median survival time (MST) of 12 months. In subgroup analyses, the PORT patients revealed a MST of 11 months and 2 year overall survival (OS) rates were 17.2%, the patients with post-operative CCRT with or without adjuvant TMZ revealed a MST of 23 months and 2 year OS rates were 38.2%. The MST of patients by Recursive Partitioning Analysis (RPA), classifications III, IV, V, VI were 26.8 months, 14.2 months, 9.9 months, and 4.0 months, (p <0.001). Conclusions: The MST of the patients who had post-operative CCRT with or without adjuvant TMZ was better than the PORT group. The RPA classification can be used to predict survival. Multimodality therapy demonstrated the most effective treatment outcome. Temozolomide might be beneficial for GBM patients in order to increase survival time.

Keywords: Glioblastoma multiforme; post-operative radiotherapy; median survival time; survival rate.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Survival Curve of GBM (Months)
Figure 2
Figure 2
Survival Time in Months of Post-operative GBM Patients with “PORT Group” Versus “ Post-operative CCRT± Adjuvant TMZ Group “.
Figure 3
Figure 3
Mean Survival Time in Months of GBM in Each Treatment Modality
Figure 4
Figure 4
Survival Time of GBM Patients in Each RPA Classification (Months)
See this image and copyright information in PMC

References

    1. Ahmadloo N, Kani AA, Mohammadianpanah M, et al. Treatment outcome and prognostic factors of adult glioblastoma multiforme. J Egypt Natl Cancer Inst. 2013;25:21–30. - PubMed
    1. Bleehen NM, Stenning SP. A medical research council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. Br J Cancer. 1991;64:769–74. - PMC - PubMed
    1. Binabaj MM, Bahrami A, ShahidSales S, et al. The prognostic value of MGMT promoter methylation in glioblastoma:A meta-analysis of clinical trials. J Cell Physiol. 2018;233:378–86. - PubMed
    1. Combs SE, Wagner J, Bischof M, et al. Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int J Radiat Oncol Biol Phys. 2008;70:987–92. - PubMed
    1. Curran WJ, Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85:704–10. - PubMed